All Posts Tagged With: "DYAX"
(CBST) Cubist Pharmaceuticals Ends Drug Trial
Cubist Pharmaceuticals Inc. (CBST) has stopped a mid-stage trial of one of its pipeline candidates, CB-500,929 (ecallantide). The drug was being studied for lowering blood loss in patients undergoing cardiac...
(CBST) Cubist to Aquire Calixa Therapeutics
Recently, Cubist Pharmaceuticals (CBST) decided to acquire a privately held biopharmaceutical company Calixa Therapeutics for an upfront payment of $92.5 million. Additionally, Cubist would be required to...